Progress in the Control of Oral Anticoagulation

Summary

It should be realized that the quality of oral anticoagulation depends on thorough pharmacological knowledge of coumarin congeners, skilled clinical supervision of the patient and well-standardized laboratory control of patients’ blood. Results of the laboratory control should no longer be expressed in terms of conventional prolongation ratios or percentages only. Exact data as to laboratory standardization with reference plasmas and the results of translation into terms of reference thromboplastins have to be given.

• References

• 1 Alexander B, de Vries A, and Goldstein R. 1949; Prothrombin: critique of methods for its determination and their clinical significance. New England Journal of Medicine 240: 403.
• 2 Allen E. V, Barker N. W, and Waugh J. M. 1942; A preparation from spoiled sweet clover (3,3′-methylene-bis-4-hydroxycoumarin) which prolongs coagulation and prothrombin time of the blood: a clinical study. Journal of the American Medical Association 120: 1009.
• 3 Bailey E. L, Harper T. A, and Pinkerton P. H. 1971; The “therapeutic range” of the one-stage prothrombin time in the control of anticoagulant therapy: the effect of different thromboplastin preparations. Canadian Medical Association Journal 105: 1041.
• 4 Bangham D. R, Biggs R, Brozovic M, and Denson K. W. E. 1970; Draft report of a collaborative study of two thromboplastins (including the use of common abnormal plasma). Thrombosis et Diathesis Haemorrhagica Supplement 40: 341.
• 5 Biggs R, and Denson K. W. E. 1967; Standardization of the one-stage prothrombin time for the control of anticoagulant therapy. British Medical Journal 1: 84.
• 6 Biggs R. 1967; The standardization of the prothrombin time for the control of anticoagulant therapy. Thrombosis et Diathesis Haemorrhagica Supplement 35: 87.
• 7 Biggs R, and Bangham D. R. 1971; Standardization of the one-stage prothrombin time test for the control of anticoagulant therapy: availability and use of thromboplastin reference preparations. British Medical Journal 3: 470.
• 8 Borchgrevink C. F. 1960 Long-term anticoagulant therapy in angina pectoris and myocardial infarction. Acta medica Scandinavica Supplement 359.
• 9 Brown K. W. G, and MacMillan R. L. 1965; Anticoagulant therapy in coronary artery disease : a therapeutic enigma. Canadian Medical Association Journal 92: 70.
• 10 Denson K. W. E. 1961; Levels of blood-coagulation factors during anticoagulant therapy with phenindione. British Medical Journal 1: 1205.
• 11 Denson K. W. E. 1971; International and national standardization of control of anticoagulant therapy in patients receiving coumarin and indanedione drugs using calibrated thromboplastin preparations. Journal of Clinical Pathology 24: 460.
• 12 Fullerton H. W. 1940; Estimation of prothrombin. A simplified method. Lancet 2: 195.
• 13 Hamming J. J, Hensen A, and Loeliger E. A. 1965; The value of long-term coumarin treatment in peripheral sclerosis (clinical trial). Thrombosis et Diathesis Haemorrhagica Supplement 21: 405.
• 14 Hemker H. C, Veltkamp J. J, Hensen A, and Loeliger E. A. 1963; On the nature of prothrombin biosynthesis. Nature 200: 589.
• 15 Hemker H. C, Veltkamp J. J, and Loeliger E. A. 1968; Kinetic aspects of the interaction of blood clotting enzymes. III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thrombosis et Diathesis Haemorrhagica 19: 346.
• 16 Hemker H. C, Muller A. M, and Loeliger E. A. 1970; Two types of prothrombin in vitamin K deficiency. Thrombosis et Diathesis Haemorrhagica 23: 633.
• 17 Progress in the Control of Oral Anticoagulation. Hill H. B, Low E. M. Y, and Schoen I. 1970; Technical factors affecting the prothrombin time determination. American Journal of Clinical Pathology 54: 348.
• 18 Horn P. van. 1968; Quality control of prothrombin determinations normal and abnormal prothrombin activity levels. American Journal of Medical Technology 34: 1.
• 19 Hurn M, and Barker N. W. 1945; The determination of prothrombin time following the administration of dicumarol, 3,3′-methylene bis-(4-hydroxycoumarin) with special reference to thromboplastin. Journal of Laboratory and Clinical Medicine 30: 432.
• 20 Jordan F. L. J. 1958; Organization of the “Thrombosis Service” in the Netherlands. Thrombosis et Diathesis Haemorrhagica 2: 527.
• 21 Josso F, Lavergne J. M, Gonault M, Prou-Wartelle O, and Soulier J. P. 1968; Différents états moléculaires du facteur II (prothrombine). Leur étude à l’aide de la staphy-locoagulase et d’anticorps antifacteur II. Thrombosis et Diathesis Haemorrhagica 20: 88.
• 22 Koller F, Loeliger E. A, and Duckert F. 1951; Experiments on a new clotting factor (factor VII). Acta haematologica 6: 1.
• 23 Larrieu M. J, and Meyer D. 1970; Abnormal factor IX during anticoagulant treatment. Lancet 2: 1085.
• 24 Leader of the Lancet. 1969; Control of anticoagulant treatment. Lancet 2: 990.
• 25 Lempert H, and Poller L. 1960; Evaluation of thrombotest in the control of anticoagulant therapy. Lancet 2: 1115.
• 26 Link K. P. 1959; The discovery of dicumarol and its sequels. Circulation 19: 97.
• 27 Loeliger E. A. 1958; Schlechte Eigenschaft langwirkender Cumarine oder für deren Kontrolle ungeeignete Thrombokinase ?. Schweizerische medizinische Wochenschrift 88: 639.
• 28 Loeliger E. A, Hensen A, Kroes F, van Dijk L. M, Fekkes N, de Jonge H, and Hemker H. C. 1967; A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta medica Scandinavica 182: 549.
• 29 Loeliger E. A, Meuwisse-Braun J. B, Muís H, Buitendijk F. J. J, Veltkamp J. J, and Hemker H. C. 1970; Laboratory control of oral anticoagulants. Definition of therapeutic range in terms of different thromboplastin preparations. Thrombosis et Diathesis Haemorrhagica 23: 569.
• 30 Loeliger E. A, and Hemker H. C. 1970; Control of long-term anticoagulant treatment. Lancet 1: 894.
• 31 Loeliger E. A, Buitendijk F. J. J, and Beitsma G. (in preparation): A uniform biochemical term of expressing results obtained with different assay procedures and thromboplastin preparations.
• 32 Loeliger E. A. Personal experience.
• 33 Mann F. D. 1968; A simple rule for control of anticoagulant therapy. Postgraduate Medicine 44: 55.
• 34 Meuwissen O. J. A. Th, Vervoorn A. C, Cohen O, Jordan F. L. J, and Nelemans F. A. 1969; Double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta medica Scandinavica 186: 361.
• 35 Meyler L, and Herxheimer A. 1968 Side effects of drugs. Vol. VI, 463–464. Excerpta Medica Foundation, Amsterdam.
• 36 Miale J. B, and Lafond D. 1967; 1963 Prothrombin time test survey, College of American Pathologists, Standard Committee, Subcommittee on Coagulation. American Journal of Clinical Pathology 47: 40.
• 37 Míale J. B, and Lafond D. 1969; Prothrombin time standardization. Proposal of the Standards Committee, College of American Pathologists, Subcommittee on Coagulation Reagents. American Journal of Clinical Pathology 52: 154.
• 38 Miale J. B, and Kent J. W. 1972; Standardization of the therapeutic range for oral anticoagulants based on standard reference plasmas. American Journal of Clinical Pathology 57: 80.
• 39 Moore C. B, and Beeler M. F. 1961; Thrombotest versus one-stage prothrombin-time determination. New England Journal of Medicine 264: 681.
• 40 Moschos C. B, Wong P. C. Y, and Sise H. S. 1964; Controlled study of the effective level of long-term anticoagulation. Journal of the American Medical Association 190: 799.
• 41 Nilehn J. E, and Ganrot P. O. 1968; Plasma prothrombin during treatment with dicumarol. Scandinavian Journal of Clinical and Laboratory Investigation 22: 17.
• 42 O’Reilly R. A, and Aggeler P. M. 1970; Determinants of the response to oral anticoagulant drugs in man. Pharmacological Reviews 22: 35.
• 43 Owren P. A, and Aas K. 1951; Control of dicoumarol therapy and quantitative determination of prothrombin and proconvertin. Scandinavian Journal of Clinical and Laboratory Investigation 3: 201.
• 44 Owren P. A. 1959; Thrombotest. A new method for controlling anticoagulant therapy. Lancet 2: 754.
• 45 Poller L. 1962; Methods for the laboratory control of short-term anticoagulant therapy. Acta haematologica 28: 168.
• 46 Poller L. 1967; A national standard for anticoagulant therapy. The Manchester Comparative Reagent. Lancet 1: 491.
• 47 Poller L, and Thomson I. M. 1968; National survey of value of plasma standards for anticoagulant therapy. British Medical Journal 2: 88.
• 48 Poller L. 1970; a Prothrombin time standardization. American Journal of Clinical Pathology 54: 670.
• 49 Poller L. 1970; b The British Comparative Thromboplastin and its quality control. Thrombosis et Diathesis Haemorrhagica. Supplement 40: 353.
• 50 Quick A. J, and Leu M. 1937; Quantitative determination of prothrombin. Journal of Biological Chemistry 119: Lxxxi.
• 51 Quick A. J, and Hussey C. V. 1961; Comparison of the thrombotest with the one-stage prothrombin time. New England Journal of Medicine 265: 1286.
• 52 Rabiner S. F. 1965; The relationship of coagulation defects to haemorrhage in patients receiving oral anticoagulants. American Journal of Medical Science 249: 68.
• 53 Rapaport S. I, and Ames S. B. 1962; Relation between levels of plasma thromboplastin component (PTC) and prothrombin times by the P & P and Quick methods in patients receiving warfarin. New England Journal of Medicine 267: 125.
• 54 Rodman Th, and Pastor B. H. 1962; Control of anticoagulant therapy with the thrombotest. Journal of the American Medical Association 180: 739.
• 55 Rozenberg M. C, Kronenberg H, and Firkin B. G. 1965; “Thrombotest” and prothrombin time : a controlled clinical trial. Australasian Annals of Medicine 14: 3.
• 56 Salzman E. W, Harris W. H, and DeSanctis R. W. 1966; Anticoagulation for prevention of thromboembolism following fractures of the hip. England Journal of Medicine 275: 122.
• 57 Seaman A. J. 1960; Owren’s capillary blood thrombotest for office or bedside control of anticoagulant therapy: an evaluation. Annals of Internal Medicine 53: 914.
• 58 Sevitt S. 1962; Venous thrombosis and pulmonary embolism. American Journal of Medicine 33: 703.
• 59 Sevitt S, and Innés D. 1964; Prothrombin-time and thrombotest in injured patients on prophylactic anticoagulant therapy. Lancet 1: 124.
• 60 Sheiner L. B. 1969; Computer-aided long-term anticoagulation therapy. Comparative Bio-medicine Research 2: 507.
• 61 Sise H. S. 1958; Relation of haemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. New England Journal of Medicine 259: 266.
• 62 Subcommittee for the Control of Anticoagulant Therapy. 1964; Report to the MRC Working Party on Anticoagulant Therapy in Coronary Thrombosis. Journal of Clinical Pathology 17: 531.
• 63 Tat R. J, and Lewis A. E. 1962; Levels of equivalence for various measurements of coumarin activity. Journal of the American Medical Association 180: 744.
• 64 Veltkamp J. J, Drion X. F, and Loeliger E. A. 1968; Detection of the carrier state in hereditary coagulation disorders. I. Thrombosis et Diathesis Haemorrhagica 19: 279.
• 65 Veltkamp J. J, Muís H, Müller A. D, Hemker H. C, and Loeliger E. A. 1971; Additional evidence for the existance of a precursor molecule of the prothrombin complex in oral anticoagulation. Thrombosis et Diathesis Haemorrhagica 25: 312.
• 66 Vries S. I. de, Abels J, Haanen C, and Loeliger E. A. 1961; De thrombotest van Owren. Nederlandsch tijdschrift voor geneeskunde 105: 977.
• 67 Ware A. G, and Stragnell R. 1952; Improved one-stage prothrombin method. American Journal of Clinical Pathology 22: 791.
• 68 Working Party on Anticoagulant Treatment in Coronary Thrombosis. 1969; Report to the Medical Research Council : Assessment of short-term anticoagulant administration after cardiac infarction. British Medical Journal 1: 335.
• 69 Zucker S, Cathey M. H, and West B. 1970; a Preparation of quality control specimens for coagulation. American Journal of Clinical Pathology 53: 924.
• 70 Zucker S, Cathey M. H, Sox P. J, and Hall E. C. 1970; b Standardization of laboratory tests for controlling anticoagulant therapy. American Journal of Clinical Pathology 53: 348.
• 71 Zucker S, Brosious E, and Cooper G. R. 1970; c One-stage prothrombin time survey. American Journal of Clinical Pathology 53: 340.
• 72 Zweifler A. J, Coon W. W, and Willis P. W. 1966; Bleeding during oral anticoagulant therapy. American Heart Journal 71: 118.